Serum IgM, IgG and IgA block by F(ab′)2-dependent mechanism the binding of natural IgG autoantibodies from therapeutic immunoglobulin preparations to self-antigens

European Journal of Haematology

Volumn 74, Issue 2, 2005, Pages 101-110

  Djoumerska, Iglika K ^a   Tchorbanov, Andrey I ^a   Donkova Petrini, Vladimira D ^a,c   Pashov, Anastas D ^b,d   Vassilev, Tchavdar L ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^c INSERM   (France)

^d UAMC   (United States)

Author keywords

Autoimmunity; Idiotype interactions; IVIg; Natural autoantibodies

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; PLASMA PROTEIN;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNE DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DENATURATION; RISK BENEFIT ANALYSIS; TWO DIMENSIONAL ELECTROPHORESIS;

ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; LIVER; PROTEIN BINDING;

EID: 12944273535     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00350.x     Document Type: Article

References (50)

1. KAZATCHKINE MD, KAVERI SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
2. PYNE D, EHRENSTEIN M, MORRIS V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002;41:367-374.
3. SIMON HU, SPATH PJ. IVIG-mechanisms of action. Allergy 2003;58:543-552.
4. AVRAMEAS S, GUILBERT B, DIGHIERO G. Natural antibodies against tubulin, actin, myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera and monoclonal immunoglobulins from multiple myeloma and Waldenstrom's macroglobulinemia may express similar antibody specificities. Ann Inst Pasteur Immunol 1981;132C:231-236.
5. AVRAMEAS S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991;12:154-159.
6. COUTINHO A., KAZATCHKINE MD, AVRAMEAS S. Natural autoantibodies. Curr Opin Immunol 1995;7:812-818.
7. MANIVEL V, BAYIROGLU F, SIDDIQUI Z, SALUNKE DM, RAO KVS. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J Immunol 2002;169:888-897.
8. PASHOV A, KENDEROV A, KYURKCHIEV S, KEHAYOV I, HRISTOVA S, LACROIX-DESMAZES S, GILTIAY N, VARAMBALLI S, KAZATCHKINE MD, KAVERI SV. Autoantibodies to heat shock protein 90 in the human natural antibody repertoire. Int Immunol 2002;14:453-461.
9. CASALI P, NOTKINS AL. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 1989;10:364-368.
10. SAENKO VA, KABAKOV AE, POVERENNY AM. Hidden high-avidity anti-DNA antibodies occur in normal human gammaglobulin preparations. Immunol Lett 1992;34:1-6.
11. WANG Z, CHEN ZJ, WHEELER J, SHEN S, NOTKINS AL. Characterization of murine polyreactive antigen-binding B cells: presentation of antigens to T cells. Eur J Immunol 2001;31:1106-1114.
12. VASSILEV T, VELEVA K. Natural polyspecific autoantibodies in human colostrum. Scand J Immunol 1996;44:535-539.
13. WARDEMANN H, YURASOV S, SCHAEFER A, YOUNG JW, MEFFRE E, NUSSENZWEIG MC. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-1377.
14. KAVERI S, VASSILEV T, HUREZ V, LENGAGNE R, LEFRANC C, COT S, POULETTY P, GLOTZ D, KAZATCHKINE MD. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-869.
15. VASSILEV TL, KAZATCHKINE MD, VANHUEN JPD et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999;93:3624-3631.
16. VASSILEV TL, HUREZ V, PASHOV AD, DUBEY C, LACROIX-DESMAZES S, BELLON B, KAZATCKINE MD, KAVERI SK. Interaction of intravenous immunoglobulin with molecules and cells of the immune system. In: KAZATCHKINE MD, MORELL A, eds. Intravenous Immunoglobulin and Therapy. New York: Parthenon, 1996:95-102.
17. MARCHALONIS JJ, KAYMAZ H, DEDEOGLU, F, SCHLUTTER SF, YOCUM DE, EDMUNDSON AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992;89:3325-3329.
18. DRUET E, PRADDAUDE F, DRUET P, DIETRICH G. Non-immunoglobulin serum proteins prevent the binding of IgG from normal rats and from rats with Th2-mediated autoimmune glomerulonephritis to various autoantigens including glomerular antigens. Eur J Immunol 1998;28:183-192.
19. HUREZ V, KAZATCHKINE MD, VASSILEV T, RAMANATHAN S, BASUYAUX B, PASHOV A, DE-KOZAK Y, BELLON B, KAVERI SV. Pooled normal human polyspecific IgM contains neutrlyzing antiidiotypes to IgG autoantibdies of autoimmune patients and protects from autoimmune disease. Blood 1997;90:4004-4013.
20. ADIB M, RAGIMBEAU J, AVRAMEAS S, TERNYNCK T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol 1990;145:3807-3813.
21. MELERO J, TARRAGO D, NUNEZ-ROLDAN, A, SANCHEZ B. Human polyreactive IgM monoclonal antibodies with blocking activity against self-reactive IgG. Scand J Immunol 1997;45:393-400.
22. STAFFORD HA, ANDERSON CJ, REICHLIN M. Unmasking of anti-ribosomal P autoantibodies in healthy individuals. J Immunol 1995;155:274-2761.
23. CABIEDES J, CABRAL AR, ALARCON-SEGOVIA D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol 1998;28:2108-2114.
24. MOUTHON L, NOBREGA A, NICOLAS N, KAVERI SV, BARREAU C, COUTINHO A, KAZATCHKINE MD. Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci USA 1995;92:3839-3843.
25. LACROIX-DESMAZES S, MOUTHON L, COUTINHO A, KAZATCHKINE MD. Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur J Immunol 1995;25:2598-2604.
26. STAHL D, VENETZ JP, LACROIX-DESMAZES S, RONDEAU E, BONNIN E, KAZATCHKINE MD, RONCO P, KAVERI SV. Idiopathic membranous glomerulonephritis is associated with altered patterns of self-reactive IgM and IgG antibody repertoires. Scand J Immunol 2001;54:534-542.
27. STAHL D, LACROIX-DESMAZES S, MOUTHON L, KAVERI SV, KAZATCHKINE MD. Analysis of human self-reactive antibody repertoires by quantitative immunoblotting. J Immunol Meth 2000;240:1-14.
28. BOUVET JP, STAHL D, ROSE S, QUAN CP, KAZATCHKINE MD, KAVERI SK. Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociation agents. J Autoimmun 2000;16:163-172.
29. MCMAHON MJ, OKENNEDY R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Meth 2000;241:1-10.
30. DEBRE M, BONNET MC, FRIDMAN WH. CAROSELLA E, PHILIPPE N, REINERT P, VILMER E, CAPLAN C, TEILLAUD JL, GRISCELLI C. Infusion of Fcg fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-949.
31. OSBORN AH, KELLEHER M, HANDMAN E, CODING JW. Anti-galactosyl antibodies that react with unmodified agarose: a potential source of artifacts in immunoaffinity chromatography. Anal Biochem 1994;217:181-184.
32. AYOUBA A, PELTRE G, COUTINHO A. Quantitative analysis of multiple V-region interactions among normal human IgG. Eur J Immunol 1996;26:710-716.
33. TANKERSLEY DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994;139:159-172.
34. VASSILEV T, BINEVA, I, DIETRICH G, KAVERI SV, KAZATCHKINE MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995;8:405-413.
35. TEELING JL, JANSEN-HENDRIKS T, KUUPERS TW, DE HAAS M, VAN DE WINKEL JG, HACK CE, BLEEKER WK. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001;98:1095-1099.
36. ROSSI F, KAZATCHKINE MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143:4104-4109.
37. ROSSI F, JAYNE DRW, LOCKWOOD CM, KAZATCHKINE MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991;83:298-303.
38. BLEEKER WK, TEELING JL, HACK, CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001;98:3136-3142.
39. DIETRICH G, ALGIMAN M, SULTAN Y, NYDEGGER UE, KAZATCHKINE MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992;79:2946-2951.
40. KAZATCHKINE MD, DIETRICH G, HUREZ V, RONDA N, BELLON B, ROSSI F, KAVERI SV. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol Rev 1994;139:79-107.
41. YU Z, LENNON VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Eng J Med 1999;340:227-228.
42. SIGOUNAS G, HARINDRANATH N, DONADEL G. NOTKINS AL. Half-life of polyreactive antibodies. J Clin Immunol 1994;14:134-140.
43. AYOUBA A, FERREIRA C, COUTINHO A. Distinguishable patterns of connectivity in serum immunoglobulins from SLE patients and healthy individuals. Scand J Immunol 1997;45:408-416.
44. RONDA N, HAURY M, NOBREGA A, KAVERI SV, COUTINHO A, KAZATCHKINE MD. Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. Int Immunol 1994;6:1651-1660.
45. STAHL D, LACROIX-DESMAZES S, HEUDES D, MOUTHON L, KAVERI SV, KAZATCHKINE MD. Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. Blood 2000;95:328-335.
46. HONG R, AMMAN AJ. Disorders of the IgA system. In: STIEM ER, ed. Immunologic Disorders in Infants and Children. Philadelphia, PA: Saunders, 1989:329-342.
47. LIBLAU RS, BACH JF. Selective IgA deficiency and autoimmunity. International Arch Allergy Immunol 1992;99:16-27.
48. RANKIN EC, ISENBERG DA. IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus 1997;6:390-394.
49. QUAN CP, WATANABE S, FORESTIER F, BOUVET JP. Human amniotic IgA inhibits natural IgG autoantibodies of maternal or unrelated origin. Eur J Immunol 1998;28:4001-4009.
50. VASSILEV T, YAMAMOTO M, AISSAOUI A, BONNIN E, BERIHAKNIN S, KAZATCHKINE M, KAVERI SK. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 1999;29:2436-2442.